Erratum to: Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells (International Journal of Cancer, (1999), 81, 2, (299-304), 10.1002/(SICI)1097-0215(19990412)81:2<299::AID-IJC21>3.0.CO;2-8);Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells

International Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 299-304

  Salerno, Michele ^a,b   Sisci, Diego ^a,b   Mauro, Loredana ^a,b   Guvakova, Marina A ^a   Ando, Sebastiano ^b   Surmacz, Ewa ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; FULVESTRANT; INSULIN RECEPTOR SUBSTRATE 1; SOMATOMEDIN; TOSYLARGININE METHYL ESTER;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 0032912182     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.33274     Document Type: Erratum

References (21)

1. ARAKI, E., HAAG, B.L., MATSUDA, K., SHICHIRI, M. and KAHN, C.R., Characterization and regulation of the mouse insulin receptor substrate gene promoter. Mol. Endocrinol., 9, 1367-1379 (1995).
2. CHANDER, S.K., SAHOTA, S.S., EVANS, T.R.J. and LUQMANI, Y.A., The biological evaluation of novel antiestrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol., 15, 243-269 (1993).
3. DE CUPIS, A. and FAVONI, R.E., Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antiestrogens. Trends Pharmacol. Sci., 18, 245-251 (1997).
4. DE CUPIS, A., NOONAN, D., PIRANI, P., FERRERA, A., CLERICO, L. and FAVONI, R.E., Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol-and IGF-I-induced proliferation of human breast cancer-derived cells. Brit. J. Pharmacol., 116, 2391-2400 (1995).
5. FREISS, G., PUECH, C. and VIGNON, F., Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated FAS-associated protein tyrosine phosphalase-1 in human breast cancer cells. Mol. Endocrinol., 12, 568-579 (1998).
6. GUVAKOVA, M.A. and SURMACZ, E., Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res., 57, 2606-2610 (1997).
7. HANKINSON, S., WILLET, W.C., COLDITZ, G., HUNTER, D.J., MICHAUD, D.S., DEROO, B., ROSNER, B., SPEIZER, F. and POLLAK, M., Circulating concentrations of insulin-like growth factor 1 and risk of breast cancer. Lancet, 351, 1393-1396 (1998).
8. LARSEN, S.S., MADSEN, M.W., JENSEN, B.L. and LYKKESFELDT, A.E., Resistance of human breast cancer cells to the pure steroidal antiestrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int. J. Cancer, 72, 1129-1136 (1997).
9. MATSUDA, K., ARAKI, E., YOSHIMURA, R., TSURUZOE, K., FURUKAWA, N., KANEKO, K., MOTOSHIMA, H., YOSHIZATO, K., KISHIKAWA, K. and SHICHIRI, M., Cell-specific regulation of IRS-1 gene expression: role of E box and C/EBP binding site in HepG2 cells and CHO cells. Diabetes, 46, 354-362 (1997).
10. NICHOLSON, R.I., GEE, J.M., BRYANT, S., FRANCIS, A.B., MCCLELLAND, R.A., KNOWLDEN, J., WAKELING, A.E. and OSBORNE, C.K., Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann. N. Y. Acad. Sci., 784, 325-335 (1996).
11. NICHOLSON, R.I., GEE, J.M., MANNING, D.L., WAKELING, A.E., MONTANO, M.M. and KATZENELLENBOGEN, B.S., Responses to pure antiestrogens (ICI 164,384, ICI 182,780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann. N. Y. Acad. Sci., 761, 148-163 (1995).
12. NISHIYAMA, M. and WANDS, J.R., Cloning and increased expression of an insulin receptor substrate 1-like gene in human hepatocellular carcinoma. Biochem. biophys. Res. Comm., 183, 280-285 (1992).
13. OSBORNE, C.K., CORONADO-HEINSOHN, E.B., HILSENBECK, S.G., MCCUE, B.L., WAKELING, A.E., MCCLELLAND, R.A., MANNING, D.L. and NICHOLSON, R.I., Comparison of the effects of a pure antiestrogen with those of tamoxifen in a model of human breast cancer. J. nat. Cancer Inst., 87, 746-750 (1995).
14. PAVLIK, E.J., NELSON, K., SRINIVVASAN, S., DEPRIEST, P.D. and KENADY, D.E., Antiestrogen resistance in human breast cancer. In E.J. Pavlik (ed.), Estrogens, progestins, and their antagonists, Vol. 1, pp. 116-159. Birkhauser. Boston (1996).
15. RESNIK, J.L., REICHART, D.B., HUEY, K., WEBSTER, N.J.G. and SEELY, B.L., Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res., 58, 1159-1164 (1998).
16. ROCHA, R.L., HILSENBECK, S.G., JACKSON, J.G. and YEE, D., Insulin-like growth factor binding protein-3 (IGFBP3) and insulin receptor substrate (IRS1) in primary breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res., 3, 103-109 (1997).
17. SURMACZ, E. and BURGAUD, J.-L., Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin. Cancer Res., 1, 1429-1436 (1995).
18. SURMACZ, E., GUVAKOVA, M.A., NOLAN, M.K., NICOSIA, R. and SCIACCA, L., Type 1 insulin-like growth factor receptor function in breast cancer. Breast Cancer Res. Treat., 47, 255-267 (1998).
19. TURNER, B.C., HAFFTY, B.G., NAYARANNAN, L., YUAN, J., HAVRE, P.A., GUMBS, A., KAPLAN, L., BURGAUD, J.-L., CARTER, D., BASERGA, R. and GLAZER, P., IGF-IR and cyclin D1 expression influence cellular radiosensitivity and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57, 3079-3083 (1997).
20. WAKELING, A.E., DUKES, M. and BOWLER, J., A potent specific pure antiestrogen with clinical potential. Cancer Res., 51, 3867-3873 (1991).
21. WISEMAN, L.R., JOHNSON, M.D., WAKELING, A.E., LYKKESFELDT, A.E., MAY, F.E. and WESTLEY, B.R., Type 1 IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer. Europ. J. Cancer. 29A, 2256-2264 (1993).